For the third straight year, Louis P. Kassa III, MPA, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), has been chosen by the Philadelphia Business Journal for its 2025 Power 100 list, which can be found here.

Pennsylvania State Sen. Steve Santarsiero of Bucks County, a strong supporter of the three nonprofits that Kassa leads, said, “It is no surprise that Lou continues to get attention for his growing influential role in the nation’s biotech industry by promoting the exceptional nonprofit model of nurturing independent research into viable commercial ventures that improve health outcomes.”

The Philadelphia Business Journal noted that Kassa now is implementing the successful PABC model elsewhere. Last fall the State of New York selected the Blumberg Institute, which operates the PABC, to manage a life sciences incubator that will be part of a planned $430 million cell and gene therapy campus on Long Island.

Kassa was executive vice president and chief operating officer of the three Doylestown nonprofits he now heads from 2014 to 2022. He was named one of the “10 Best COOs of 2020” by Industry Era, a global publication.

A Bucks County resident, Kassa earned an undergraduate degree at the Pennsylvania State University and a Master of Public Administration from Villanova University.

Kassa is a board member of numerous organizations: Bucks County Workforce Development Board, Central Bucks Chamber of Commerce, Startup Bucks, Yards Sciences, Bucks County Music Project, Family Foundations Partnership and Triumph in Recovery.

About the Hepatitis B Foundation: As the world’s leading hepatitis B advocacy and research organization, the Hepatitis B Foundation is one of the most active proponents of improving hepatitis B screening, prevention and treatment. We are the only nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with teams in Washington, D.C., and Philadelphia. For more, go to www.hepb.org, read our blog, hepb.org/blog, follow us on Twitter, Instagram and Facebook (@hepbfoundation) or call us at 215-489-4900.

About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is a leading center for translational research in hepatitis B, liver cancer and related diseases. The Blumberg Institute operates in the Pennsylvania Biotechnology Center (PABC), which it manages, in Doylestown, Pa. The Institute also runs a state-of-the-art incubator in Philadelphia, B+labs at Cira Centre, which is a partnership with Brandywine Realty Trust. Visit our website and follow us on LinkedIn and X, @BlumbergInstit1.

About the Pennsylvania Biotechnology Center (PABC): The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology and maximize synergies among nonprofit scientists and their commercial colleagues. The PABC has more than 90 member companies and organizations, mostly small to mid-size science, research and pharmaceutical companies. Nearly 50 of those companies operate on the Doylestown campus, which is home to the Hepatitis B Foundation and the Blumberg Institute. The PABC also manages B+labs at Cira Centre, an incubator in Philadelphia with 19 resident companies, in partnership with Brandywine Realty Trust. PABC companies have produced numerous FDA-approved drugs and medical devices, and a recent study found that the PABC’s economic impact exceeded $7.3 billion and created more than 1,100 new jobs during 2016-2021. Please visit our website and follow us on LinkedIn, Instagram, Twitter (@BiotechnologyPa) and Facebook.